B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country.

The B7451015 study also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI. The sub-study will be conducted in selected countries at selected sites. Eligible subjects are those who were 12 to \<18 years of age at the screening visit of the qualifying parent study and who are currently participating in the main B7451015 study. The sub-study will include serial Magnetic Resonance Imaging (MRI) annually and continue until all enrolled subjects are 18 years of age and have been imaged at least once or have discontinued/withdrawn.

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Pflugerville, TX

San Antonio, Texas

San Antonio, TX

Arlington, TX

Monterrey, Mexico

Saint Joseph, MO

Veracruz, Mexico

JM Research SC

Owensboro, KY

Merida, Mexico

Normal, IL

Plainfield, IN

Tampa, FL

Indianapolis, IN

Jacksonville, FL

Rapid City, SD

Shelby, NC

Minneapolis, MN

Bexley, OH

Miami Lakes, FL

Boca Raton, FL

Miami, FL

Clinical Research Site

Greensboro - Cardiology

San Diego, CA

Encinitas, CA

Windsor, Canada

Clarkston, MI

Troy, MI

Derm Center

HQ, Irvine, CA

Fountain Valley, CA

Santa Monica, CA

London, Canada

Rockville, MD

Norfolk, VA

Oakvile, Canada

Mississauga, Canada

White Marsh, MD

Toronto, Canada

Ontario, Canada

Richmond Hill, Canada

Ontario, CA

Barrie, Canada

UR Dermatology at College Town

Sudbury, Canada

Forest Hills Dermatology Group

Spokane, WA

Calgary, Canada

Clinical Operations Department

Portland, OR

Edmonton, AB

Clinique Medicale Saint-Louis

St. Johns, NL

Sheffield Children's Hospital - Clinical Research Facility

Clinical Research Unit

Luigi Sacco University Hospital - Gastroenterology and Digestive Endoscopy Department

Wroclaw, Poland

Warsaw, Poland

Krakow, Poland

Benowa, Australia

Santa Ana, CA

Maroubra

East Melbourne, Australia

Carlton, Australia

Pfizer

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Bellaire, TX

McGovern Medical School - ACTAT - Research Department

Texas Medical Center

Plano, TX

Oklahoma City, OK

Hot Springs, AR

North Little Rock

Albuquerque, NM

Dermatology and Skin Cancer Center Leawood

SLUCare Academic Pavilion - Endocrinology Division Research

Lincoln, NE

Research Center

Scottsdale, AZ

West Lafayette, Indiana

Charlotte, NC

Las Vegas, NV

Hialeah, FL

Coral Gables, FL

Long Beach, CA

Los Angeles, CA

Northridge, CA

Canoga Park, California

Bakersfield, CA

Internal Medicine Glennan Center for Geriatrics and Gerontology

Waterloo, Canada

Chevy Chase, MD

Hamilton, Canada

Burlington, Canada

Towson, MD

Niagara Falls, Canada

Camp Hill, PA

Boise, ID

Newmarket, Canada

Reno - Moana Lane Location

Sacramento, CA

Dublin, CA

Department of Cardiology

New York, NY

Jose Garcia, Coordinator

Saskatoon, Canada

Ottawa, Canada

Clinical Research Institute of Southern Oregon (CRISOR)

Kelowna, Canada

 Edmonton, Canada

Vida Dermatology South

San Juan, PR

Santiago, Chile

Maldegem, Belgium

Buenos Aires, Argentina

Remscheid, Germany

Hannover, Germany

Haematology Department

Tartu, Estonia

Clinical Trial Center

Szolnok, Hungary

Nagoya City University Hospital

Amgen

The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are:

Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis.

Participants will:

Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks.

Keep a diary of when they use the product and complete a form about their symptoms including itching.

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Austin, TX

Aesthetix Dermatology of Fort Lauderdale

Fremont, CA

Brighton, MA

CAGE Bio

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Cypress, TX

Dallas, TX

Dawsonville, GA

Coral Springs - Oncology

Margate, FL

 Thousand Oaks, CA

Plymouth Meeting, PA

Quincy, MA

AbbVie

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Galderma

Find clinical trials for Eczema in Austin, TX

Related conditions:

Eczema trials near Austin, TX, USA:

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Austin, TX

Related conditions:

Eczema trials near Austin, TX, USA:

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in Austin, TX